TP53 and primary central nervous system lymphoma: In conclusion, our data indicate that PCNSL have comprehensive molecular alterations in the p53-pathway, and that the high disruption frequency of the p53-pathway contributes to the poor outcome in CCT-treated PCNSL patients.